SCHEMBL5021788

SCHEMBL5021788

CC[C@H]1c2cc(c(O)cc2O)[C@@H](CC)c2cc(c(O)cc2O)[C@@H](CC)c2cc(c(O)cc2O)[C@@H](CC)c2cc1c(O)cc2O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
ALDH1A1 P00352 2/20 0.31
RECQL P46063 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
FYN P06241 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TRPA1 O75762 1/20 0.31
HMGCR P04035 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
APEX1 P27695 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23551151 1.00 ESR1 (0.33) ESR1ESR2ALDH1A1RECQLTDP1
SCHEMBL13053925 1.00 ESR1 (0.33) ESR1ESR2ALDH1A1RECQLTDP1
SCHEMBL13663784 0.91 ESR1 (0.30) ESR1ESR2
SCHEMBL13053962 0.89 KDM4E (0.33) ESR1ESR2ALDH1A1HPGDALOX15
SCHEMBL8159413 0.80 FYN (0.42) ESR1ESR2ALDH1A1RECQLTDP1
SCHEMBL13053929 0.77 PTGS2 (0.38) ALDH1A1FYNHPGDKDM4EMEN1
SCHEMBL22921087 0.75 DRD2 (0.37)
SCHEMBL13927560 0.73 FFAR1 (0.41) ESR1ALDH1A1TDP1HPGDALOX15
SCHEMBL13053963 0.73 FYN (0.37) ESR1ESR2ALDH1A1FYNHPGD
SCHEMBL24388191 0.72 FFAR1 (0.36) ESR1ALDH1A1FYNHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791092-B2 Molecular tweezers for the treatment of amyloid-related diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-29 US disclosed
US-8791092-B2 Molecular tweezers for the treatment of amyloid-related diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-29 US disclosed
US-20120108548-A1 MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-03 US disclosed
US-20120108548-A1 MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108548-A1 MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 ESR1 4289/4885ESR2 3847/4885ALDH1A1 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.